Ranking · Unmet Need
Trial Gap Index
Burden percentile minus active-trial percentile within the same scope. Positive values flag cancers with high mortality burden but comparatively few active trials. A quantitative signal, not an accusation (CLAUDE.md §324). Caveat (Phase 1): trial counts aggregate a cancer and its NCIt descendants only; registrations phrased at a broader level (e.g. "colorectal cancer" for colon and rectal cancer) are attributed to the broader entity, which can overstate the gap of narrower top-level sites.
Computedci-trial-gap-v1unit: percentile pointshigher = worseAll metrics
| Rank | Δ | Cancer | Trial Gap Index (percentile points) | Percentile | Confidence | Sources | Why #n? |
|---|---|---|---|---|---|---|---|
| 1 | = | Malignant Colon Neoplasm | +56.7 | 100 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2591599 |
| 2 | = | Cutaneous Melanoma | +20 | 96.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2591600 |
| 3 | = | Malignant Laryngeal Neoplasm | +20 | 93.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2591601 |
| 4 | = | Malignant Bladder Neoplasm | +13.3 | 90 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2591602 |
| 5 | = | Malignant Vaginal Neoplasm | +10 | 86.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2591603 |
| 5 | = | Malignant Vulvar Neoplasm | +10 | 86.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2591604 |
| 7 | = | Malignant Ovarian Neoplasm | +6.7 | 80 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2591606 |
| 7 | = | Malignant Pancreatic Neoplasm | +6.7 | 80 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2591605 |
| 9 | = | Malignant Salivary Gland Neoplasm | +3.3 | 73.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2591607 |
| 10 | = | Malignant Gastric Neoplasm | +3.3 | 70 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2591609 |
| 10 | = | Malignant Mesothelioma | +3.3 | 70 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2591608 |
| 10 | = | Malignant Prostate Neoplasm | +3.3 | 70 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2591610 |
| 13 | = | Malignant Esophageal Neoplasm | 0 | 60 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2591611 |
| 13 | = | Malignant Kidney Neoplasm | 0 | 60 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2591613 |
| 13 | = | Malignant Lung Neoplasm | 0 | 60 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2591612 |
| 13 | = | Malignant Rectal Neoplasm | 0 | 60 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2591614 |
| 17 | = | Malignant Hypopharyngeal Neoplasm | -3.3 | 46.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2591615 |
| 18 | = | Malignant Testicular Neoplasm | -3.4 | 43.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2591616 |
| 19 | = | Malignant Breast Neoplasm | -3.4 | 40 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2591617 |
| 19 | = | Malignant Central Nervous System Neoplasm | -3.4 | 40 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2591618 |
| 21 | = | Malignant Thyroid Gland Neoplasm | -6.6 | 33.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2591619 |
| 22 | = | Malignant Penile Neoplasm | -6.7 | 30 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2591620 |
| 23 | = | Hodgkin Lymphoma | -6.7 | 26.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2591621 |
| 24 | = | Leukemia | -10 | 23.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2591622 |
| 24 | = | Malignant Anal Neoplasm | -10 | 23.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2591624 |
| 24 | = | Non-Hodgkin Lymphoma | -10 | 23.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2591623 |
| 27 | = | Malignant Liver Neoplasm | -16.6 | 13.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2591625 |
| 27 | = | Malignant Uterine Corpus Neoplasm | -16.6 | 13.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2591626 |
| 29 | = | Malignant Cervical Neoplasm | -16.7 | 6.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2591627 |
| 30 | = | Multiple Myeloma | -20 | 3.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2591628 |
| 31 | = | Malignant Nasopharyngeal Neoplasm | -26.6 | 0 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2591629 |
Data updated 16 hours agoSource updated unknown31 eligible entities · inputs hash 95c073bb22fbdd5ba2aa08d1